Signal
Advances in single-cell and organoid models enhance cancer drug response prediction
Evidence first: scan the strongest sources, then decide whether to go deeper.
rss
clinical_trialsdrug_developmentr_and_dsafety_signalsgenomics
Trend in the last 24h
Current brief openSource links open
This current signal is open on the public brief with summary, metadata, source links, and full evidence. Pro adds compare-over-time, alerts, exports, and workflow.
No card needed for the free brief.
Evidence trail (top sources)
top sources (2 domains)domains are deduped. counts indicate coverage, not truth.2 top sources shown
limited source diversity in top sources
Overview
Recent studies showcase innovative platforms to improve prediction of cancer drug responses.
Score total
1.16
Momentum 24h
3
Posts
3
Origins
2
Source types
1
Duplicate ratio
0%
Why now
- Recent benchmarking reveals strengths and gaps in current single-cell drug response models.
- New machine learning platforms like SCOPE demonstrate clinical trial outcome prediction without prior trial data.
- Innovative microwell assays offer scalable, high-resolution profiling of tumor cell growth phenotypes.
Why it matters
- Improved prediction of drug response can guide personalized cancer treatment and reduce trial failures.
- Single-cell and organoid models capture tumor heterogeneity critical for understanding resistance mechanisms.
- Scalable assays and computational tools enable integration of biological and clinical data for better trial outcome forecasts.
LLM analysis
Topic mix: lowPromo risk: lowSource quality: high
Recurring claims
- Single-cell RNA sequencing enables prediction of drug response at single-cell resolution across multiple cancer types and drugs.
- Integrating patient-derived organoid drug screening with clinical data via machine learning can predict clinical trial outcomes in metastatic cancers.
- High-density microwell assays provide scalable, quantitative profiling of single-cell clonal expansion, capturing heterogeneous tumor growth behaviors.
How sources frame it
- Shen Et Al.: neutral
- Bouteiller Et Al.: neutral
- Stefanius Et Al.: neutral
All evidence
All evidence
bioRxiv and medRxiv recent cancer drug response studies
biorxiv.org · biorxiv.org · 2026-04-14 15:58 UTC
SCOPE: Integrating Organoid Screening and Clinical Variables Through Machine Learning for Cancer Trial Outcome Prediction
medRxiv (all subjects) · medrxiv.org · 2026-04-14 14:38 UTC
A Scalable High-Density Microwell Assay for Single-Cell Clonal Expansion Profiling
bioRxiv (all subjects) · biorxiv.org · 2026-04-14 21:48 UTC
Show filters & breakdown
Posts loaded: 0Publishers: 3Origin domains: 2Duplicates: -
Showing 3 / 0
Top publishers (this list)
- biorxiv.org (1)
- medRxiv (all subjects) (1)
- bioRxiv (all subjects) (1)
Top origin domains (this list)
- biorxiv.org (2)
- medrxiv.org (1)